Immunogenicity and safety of an inactivated quadrivalent influenza vaccine co-administered with a 23-valent pneumococcal polysaccharide vaccine versus separate administration, in adults ≥50 years of age: results from a phase III, randomized, non-inferiority trial

Estás aquí:
Ir a Tienda